SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients
0 references·1 citing·4 second hop
Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients (1998)Cost-utility model comparing docetaxel an…Cost‐effectiveness analysis of lapatinib in HER‐2–positive advanced breast cancer (2009)Cost‐effectiveness analysis o…Cost-Effectiveness in Health and Medicine (1996)What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation? (2003)Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis (2004)Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer (2016)
this work references cited by second hop

References

No references inside the corpus for this window.

Cited by

  • 2009Cost‐effectiveness analysis of lapatinib in HER‐2–positive advanced breast cancer57 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work